Probiotics in Disease Prevention and Treatment.

abstract：:Atorvastatin is a common option among the HMG-CoA reductase inhibitors for the treatment of lipid disorders because of its excellent lipid-lowering efficacy and overall safety profile. Although these agents can rarely cause rhabdomyolysis by themselves, macrolides, among other agents, have been demonstrated to increas...

journal_title：Journal of clinical pharmacology

authors： Amsden GW,Kuye O,Wei GC

更新日期：2002-04-01 00:00:00

abstract：:The most thorough and clinically relevant approach to hypnotic drug evaluation is one that balances the strengths and weaknesses of clinical trials and sleep laboratory evaluations. Advantages of clinical trials include the ability to evaluate large numbers of subjects and specific target groups and to thoroughly asse...

journal_title：Journal of clinical pharmacology

authors： Kales A,Scharf MB,Soldatos CR,Bixler EO

更新日期：1979-07-01 00:00:00

abstract：:The objective of this study was to investigate the influence of food on the pharmacokinetics of tolterodine, its active 5-hydroxymethyl metabolite (5-HM), and exposure to the active moiety (sum of unbound tolterodine + 5-HM) in healthy volunteers. Serum concentrations of tolterodine and 5-HM were measured for up to 12...

journal_title：Journal of clinical pharmacology

authors： Olsson B,Brynne N,Johansson C,Arnberg H

更新日期：2001-03-01 00:00:00

abstract：:In many industrialized nations, the elderly comprise the fastest growing subpopulation and constitute an increasing proportion of the total population compared to other age groups. The elderly use a disproportionately larger amount of health care resources since they experience a higher incidence of disease-related mo...

journal_title：Journal of clinical pharmacology

authors： Schmucker DL,Vesell ES

更新日期：1999-11-01 00:00:00

abstract：:This report investigated safety and dosing recommendations of intravenous caspofungin in hepatic insufficiency. In the single-dose study, 8 patients each with mild and moderate hepatic insufficiency received 70 mg of caspofungin. In the multiple-dose study, 8 patients with mild hepatic insufficiency and 13 healthy mat...

journal_title：Journal of clinical pharmacology

authors： Mistry GC,Migoya E,Deutsch PJ,Winchell G,Hesney M,Li S,Bi S,Dilzer S,Lasseter KC,Stone JA

更新日期：2007-08-01 00:00:00

abstract：:Nintedanib, a triple angiokinase inhibitor, has undergone clinical investigation for the treatment of solid tumors and idiopathic pulmonary fibrosis. Nintedanib (Vargatef® ) plus docetaxel is approved in the EU for the treatment of patients with adenocarcinoma non-small cell lung cancer (NSCLC) after first-line chemot...

journal_title：Journal of clinical pharmacology

authors： Dallinger C,Trommeshauser D,Marzin K,Liesener A,Kaiser R,Stopfer P

更新日期：2016-11-01 00:00:00

abstract：:Thirty-eight ambulatory patients with congestive cardiac failure took part in a double-blind clinical trial of 50 mg hydrochlorothiazide orally daily and slow-release formulation of 60 mg furosemide orally daily. Following a one-week period of placebo administration, patients were randomly allocated to the treatment w...

journal_title：Journal of clinical pharmacology

authors： Vermeulen A,Chadha DR

更新日期：1982-11-01 00:00:00

abstract：:The pharmacokinetic profile of solifenacin succinate (YM905; Vesicare), a new once-daily bladder-selective muscarinic receptor antagonist, was examined in 2 controlled trials of healthy young men. A single-dose study evaluated 5-, 10-, 20-, 40-, 60-, 80-, and 100-mg doses. A multidose study evaluated 5-, 10-, 20-, and...

journal_title：Journal of clinical pharmacology

authors： Smulders RA,Krauwinkel WJ,Swart PJ,Huang M

更新日期：2004-09-01 00:00:00

abstract：:The pharmacokinetics of codeine, codeine glucuronide, morphine, and morphine glucuronide were assessed after single- (60 mg) and multiple-dose (60 mg every six hours for nine doses) oral administration of codeine sulfate to six normal volunteers. Multiple blood and urine samples were collected after administration of ...

journal_title：Journal of clinical pharmacology

authors： Guay DR,Awni WM,Halstenson CE,Findlay JW,Opsahl JA,Abraham PA,Jones EC,Matzke GR

更新日期：1987-12-01 00:00:00

abstract：:Angiotensin converting enzyme (ACE) inhibitors are increasingly important in antihypertensive therapy because of their efficacy, tolerability, and specific benefits in subsets of patients. They are pharmacologically diverse. Whereas most benefits have been proven with older agents (captopril, enalopril), newer agents,...

journal_title：Journal of clinical pharmacology

authors： Burris JF

更新日期：1995-04-01 00:00:00

abstract：:GS-9667, a new selective, partial agonist of the A(1) adenosine receptor (AR), may represent an effective therapy for Type 2 diabetes (T2DM) and dyslipidemia via lowering of free fatty acids (FFA). The objectives of the studies were to evaluate the effects of single and multiple doses of GS-9667 on plasma FFA concentr...

journal_title：Journal of clinical pharmacology

authors： Staehr PM,Dhalla AK,Zack J,Wang X,Ho YL,Bingham J,Belardinelli L

更新日期：2013-04-01 00:00:00

abstract：:Piragliatin is a CYP3A substrate; its inactive metabolite M4, formed through cytosolic reductase, is reversibly metabolized back to piragliatin through CYP3A. The impact of concomitant CYP3A modifiers thus cannot be predicted. Drinking alcohol under fasting conditions is associated with a recognized glucose-lowering e...

journal_title：Journal of clinical pharmacology

authors： Zhi J,Zhai S,Georgy A,Liang Z,Boldrin M

更新日期：2016-05-01 00:00:00

abstract：:Two populations of critical care patients were studied using indices of renal tubular damage (beta 2-microglobulin, enzymes, casts) and indices of glomerular filtration (creatinine, creatinine clearance). The purpose of these studies had been initially to elucidate the type of renal failure typical of the critically i...

journal_title：Journal of clinical pharmacology

authors： Schentag JJ

更新日期：1983-10-01 00:00:00

abstract：:TAS-303 (4-piperidinyl 2,2-diphenyl-2-[propoxy-1,1,2,2,3,3,3-d7 ] acetate hydrochloride) is a novel selective noradrenaline reuptake inhibitor being developed for the treatment of stress urinary incontinence. An in vitro study and a physiologically based pharmacokinetic model simulation showed that TAS-303 had inhibit...

journal_title：Journal of clinical pharmacology

authors： Kumagai Y,Fujita T,Maeda M,Sasaki Y,Nagaoka M,Huang J,Takenaka T,Kawai M

更新日期：2020-06-01 00:00:00

abstract：:In the pivotal TEMPO 3:4 trial, the arginine vasopressin V2-receptor antagonist tolvaptan reduced the rate of kidney growth in patients with autosomal dominant polycystic kidney disease. Tolvaptan was initiated as daily morning/afternoon doses of 45/15 mg, and uptitrated weekly to 60/30 mg and 90/30 mg according to pa...

journal_title：Journal of clinical pharmacology

authors： Shoaf SE,Chapman AB,Torres VE,Ouyang J,Czerwiec FS

更新日期：2017-07-01 00:00:00

abstract：:Vildagliptin is a potent and selective dipeptidyl peptidase IV inhibitor in development for the treatment of type 2 diabetes that improves glycemic control by enhancing alpha- and beta-cell responsiveness to glucose. Two open-label, single-dose, randomized, crossover studies in healthy subjects (ages 18-45 years) inve...

journal_title：Journal of clinical pharmacology

authors： Sunkara G,Sabo R,Wang Y,He YL,Campestrini J,Rosenberg M,Howard D,Dole WP

更新日期：2007-09-01 00:00:00

abstract：:This analysis was conducted to characterize the pharmacokinetics and pharmacodynamics of pegfilgrastim and to develop a pharmacokinetic-pharmacodynamic model to describe the granulopoietic effects of pegfilgrastim and the homeostatic regulation of pegfilgrastim clearance in healthy subjects. Pegfilgrastim serum concen...

journal_title：Journal of clinical pharmacology

authors： Roskos LK,Lum P,Lockbaum P,Schwab G,Yang BB

更新日期：2006-07-01 00:00:00

abstract：:Taranabant is a cannabinoid-1 receptor inverse agonist for the treatment of obesity. This study evaluated the safety, pharmacokinetics, and pharmacodynamics of taranabant (5, 7.5, 10, or 25 mg once daily for 14 days) in 60 healthy male subjects. Taranabant was rapidly absorbed, with a median t(max) of 1.0 to 2.0 hours...

journal_title：Journal of clinical pharmacology

authors： Addy C,Rothenberg P,Li S,Majumdar A,Agrawal N,Li H,Zhong L,Yuan J,Maes A,Dunbar S,Cote J,Rosko K,Van Dyck K,De Lepeleire I,de Hoon J,Van Hecken A,Depré M,Knops A,Gottesdiener K,Stoch A,Wagner J

更新日期：2008-06-01 00:00:00

abstract：:CPX-351, a dual-drug liposomal encapsulation of cytarabine and daunorubicin at a synergistic ratio, is approved in the United States for adults with newly diagnosed therapy-related acute myeloid leukemia or acute myeloid leukemia with myelodysplasia-related changes. Population pharmacokinetics analyses were performed ...

journal_title：Journal of clinical pharmacology

authors： Wang Q,Banerjee K,Vasilinin G,Marier JF,Gibbons JA

更新日期：2019-05-01 00:00:00

abstract：:Sleep disturbances and decrements of daytime performance have been attributed to HMG-CoA reductase inhibitors. As a rule, lipophilic compounds more readily cross the blood-brain barrier and are more likely to affect central nervous system function. The authors compared the effects of lovastatin (40 mg), a lipophilic c...

journal_title：Journal of clinical pharmacology

authors： Kostis JB,Rosen RC,Wilson AC

更新日期：1994-10-01 00:00:00

abstract：:Thrombomodulin alfa is the recombinant extracellular domain of human thrombomodulin, which shows anticoagulation activity. To elucidate the pharmacokinetics of thrombomodulin alfa in patients with disseminated intravascular coagulation (DIC), population pharmacokinetic (PPK) analysis was performed using plasma concent...

journal_title：Journal of clinical pharmacology

authors： Tsuruta K,Yamada Y,Serada M,Tanigawara Y

更新日期：2011-09-01 00:00:00

abstract：:In this investigation, the pharmacokinetic and pharmacodynamic properties were determined of multiple doses of sublingual tablets containing either buprenorphine alone or buprenorphine and naloxone. Subjects were experienced opiate users who received escalating doses (4-24 mg) of buprenorphine either alone or in combi...

journal_title：Journal of clinical pharmacology

authors： Ciraulo DA,Hitzemann RJ,Somoza E,Knapp CM,Rotrosen J,Sarid-Segal O,Ciraulo AM,Greenblatt DJ,Chiang CN

更新日期：2006-02-01 00:00:00

abstract：:Respiratory syncytial virus (RSV)-associated respiratory tract infection is a leading cause of hospitalizations in infants for which no effective treatment exists. RSV infection is also an important cause of respiratory disease in adults and immunocompromised patients. Presatovir (GS-5806) is an orally bioavailable an...

journal_title：Journal of clinical pharmacology

authors： German P,Xin Y,Chien JW,Weng W,Mackman R,Lewis SA,Meng A,Ling J,Mathias A

更新日期：2018-08-01 00:00:00

abstract：:Type 2 diabetes has now reached epidemic proportions across the world and is the cause of substantial morbidity and mortality. Patients with diabetes suffer from their mircovascular complications of retinopathy (blindness), nephropathy (renal failure, dialysis), and neuropathy (neropathic pain, trophic ulcers). Howeve...

journal_title：Journal of clinical pharmacology

authors： Mudaliar S

更新日期：2004-04-01 00:00:00

abstract：:Meptazinol, m-(3-ethyl-1-methyl-hexahydro-1-H-azepin-3-yl) phenol hydrochloride is a centrally active opioid analgesic with a specificity for the mu-1 receptor. It has been reported to lack many of the side effects commonly observed with morphine and morphinelike drugs in man. The objective of this study was to assess...

journal_title：Journal of clinical pharmacology

authors： Siegel C,Sunshine A,Richman H,Olson NZ,Robissa N,Cordone R,Estrada N,Laska E

更新日期：1989-11-01 00:00:00

abstract：:There has been a considerable revolution in the field of hypertension therapy. We have gone through an era in which patients with severe hypertension and those with accelerated hypertension had a very short life expectancy. Currently blood pressure can be readily controlled with a marked improvement in longevity. We h...

journal_title：Journal of clinical pharmacology

authors： Somberg J,Ehrenpreis S,Shroff G,Khosla S

更新日期：1993-03-01 00:00:00

abstract：:Guidelines have been developed by the Bureau of Drugs, FDA, for antinflammatory drug development. They address the problem of efficacy and safety testing but leave the definition of qualified investigators and appropriate subjects unstated. The natural history of rheumatoid arthritis, the most-studied chronic inflamma...

journal_title：Journal of clinical pharmacology

authors： Ehrlich GE

更新日期：1977-11-01 00:00:00

abstract：:A pilot study of a small group of schizophrenic patients manifesting symptoms of a depressive nature was treated in a double-blind study in which viloxazine or a placebo was administered in combination with either chlorpromazine or haloperidol. There appeared to be no difference between the viloxazine-treated group an...

journal_title：Journal of clinical pharmacology

authors： Kurland AA,Nagaraju A

更新日期：1981-01-01 00:00:00

abstract：:Psychoactive drugs are often widely used before tolerance and dependence is fully appreciated. Tolerance to cannabis-induced cardiovascular and autonomic changes, decreased intraocular pressure, sleep and sleep EEG, mood and behavioral changes is acquired and, to a great degree, lost rapidly with optimal conditions. M...

journal_title：Journal of clinical pharmacology

authors： Jones RT,Benowitz NL,Herning RI

更新日期：1981-08-01 00:00:00

abstract：:US prescribing guidelines recommend that 15- and 20-mg doses of rivaroxaban be administered with food for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and for reduction in the risk of recurrence of DVT and PE. In addition, the US prescribing guidelines recommend these doses be administered w...

journal_title：Journal of clinical pharmacology

authors： Zhang L,Peters G,Haskell L,Patel P,Nandy P,Moore KT

更新日期：2017-12-01 00:00:00